Impact of COVID-19 on Sexually Transmitted Infection Burden: A Cross-Sectional Study from a Tertiary Care Hospital in Gujarat
Keywords:
Chronic Spontaneous Urticaria, Antihistamines, Dose Escalation, Antihistamine Switching, Fexofenadine, Levocetirizine, DesloratadineAbstract
Background:Chronic Spontaneous Urticaria (CSU) is a persistent skin disorder characterized by recurrent wheals, angioedema, or both, lasting for at least six weeks without an identifiable trigger. CSU significantly affects patients’ quality of life, often causing sleep disturbances, emotional distress, and reduced work productivity. First-line treatment involves second-generation H1-antihistamines, but many patients remain refractory to standard doses, necessitating dose escalation or antihistamine switching.
Objective:This study aims to evaluate the efficacy of three second-generation antihistamines—Fexofenadine, Levocetirizine, and Desloratadine—in CSU management, focusing on symptom relief, dose escalation, antihistamine switching, and adverse effects.
Methods:A prospective, observational study was conducted on 300 CSU patients at a dermatology outpatient clinic. Patients were initially treated with standard doses of Levocetirizine (5 mg), Desloratadine (5 mg), or Fexofenadine (180 mg). Non-responders underwent a stepwise dose escalation up to fourfold. Patients who remained symptomatic despite escalation were switched to a different antihistamine. Symptom severity was assessed using the Urticaria Activity Score (UAS), and adverse effects were monitored over a six-month follow-up period.
Results:Fexofenadine demonstrated superior efficacy, with 87% of patients achieving symptom relief after fourfold dose escalation, compared to 38% with Levocetirizine and 15% with Desloratadine. Antihistamine switching yielded a 31.5% response rate among non-responders, with the highest success observed when switching from Desloratadine to Levocetirizine (18.5%). Fexofenadine showed the greatest reduction in UAS at one-week (50%) and three-week (75%) follow-ups (p<0.05). Adverse effects were minimal, with headaches more common in the Fexofenadine group, while drowsiness was prevalent in Levocetirizine and Desloratadine groups.
Conclusion:Fexofenadine is the most effective antihistamine for CSU management, particularly at higher doses. Dose escalation significantly improves symptom control, while antihistamine switching benefits a subset of non-responders. Personalized treatment strategies considering patient-specific responses can enhance clinical outcomes in CSU. Future research should focus on biomarker-based therapy and combination treatments to optimize CSU management
Downloads
Metrics
References
Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real‐world evidence from ASSURE‐CSU. Allergy. 2017;72(12):2005-2016.
Tzur Bitan D, Berzin D, Cohen A. The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study. Arch Dermatol Res. 2021;313(1):33-39.
Riedl MA, Patil D, Rodrigues J, et al. Clinical burden, treatment, and disease control in patients with chronic spontaneous urticaria: Real-world evidence. Ann Allergy Asthma Immunol. 2024.
Lapi F, Cassano N, Pegoraro V, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population‐based study in Italy. Br J Dermatol. 2016;174(5):996-1004.
Giménez-Arnau AM, de Montjoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9(6):2195-2208.
Yanase Y, Takahagi S, Ozawa K, et al. The role of coagulation and complement factors for mast cell activation in the pathogenesis of chronic spontaneous urticaria. Cells. 2021;10(7):1759.
Kolkhir P, Altrichter S, Asero R, et al. Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021;13(4):545.
Kolkhir P, Altrichter S, Hawro T, et al. C‐reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73(4):940-948.
Choi WS, Lim ES, Ban GY, et al. Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria. Korean J Intern Med. 2016;33(1):185.
Weller K, Koti I, Makris M, et al. Anxiety and depression seem less common in patients with autoreactive chronic spontaneous urticaria. Clin Exp Dermatol. 2013;38(8):870-873.
Sarti L, Barni S, Giovannini M, et al. Efficacy and tolerability of the updosing of second‐generation non‐sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32(1):153-160.
Kocatürk E, Başkan EB, Küçük ÖS, et al. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?. An Bras Dermatol. 2022;97(5):592-600.
Lang DM, Sheikh J, Joshi S, et al. Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: Evolving toward personalized medicine. Ann Allergy Asthma Immunol. 2024.
Maurer M, Giménez-Arnau A, Ensina LF, et al. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ J. 2020;13(9):100460.
Maurer M, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy. 2019;49(5):655-662.
Khan DA. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract. 2013;1(5):433-440.e1.
Nelson HS, et al. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517-522.
Zuberbier T, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766.
Godse KV, Nadkarni NJ, Jani G, et al. Fexofenadine in higher doses in chronic spontaneous urticaria. Indian Dermatol Online J. 2010;1(1):45-46.
Curto-Barredo L, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol. 2018;179(1):210-212.
Potter PC, et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009;64(4):596-604.
Fukunaga A, Oda Y, Washio K, et al. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial. Trials. 2020;21(1):23.
Paul E, Berth-Jones J, Ortonne JP, et al. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: A placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat. 1998;9:143-149.
Shah B, Dhoot D, Choudhary A, et al. A comparative, three-arm, randomized clinical trial to evaluate the effectiveness and tolerability of bilastine vs fexofenadine vs levocetirizine in patients with chronic spontaneous urticaria. Clin Cosmet Investig Dermatol. 2022;15:261-270.
Podder I, Dhabal A, Chakraborty SS. Efficacy and safety of up-dosed second-generation antihistamines in uncontrolled chronic spontaneous urticaria: A review. J Clin Aesthet Dermatol. 2023;16(3):44-50.
Meeves SG, Appajosyula S, Lacouture P, et al. Efficacy and safety profile of fexofenadine HCl: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003;112(4):S69-S77.
van den Elzen MT, van Os-Medendorp H, van den Brink I, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy. 2017;7:4.
Xiang YK, Fok JS, Podder I, et al. An update on the use of antihistamines in managing chronic urticaria. Expert Opin Pharmacother. 2024;25(5):551-569.
Luo M, Shen K, Dong X, et al. Efficacy and safety of combinations of H1 antihistamines in the treatment of urticaria: A scoping review. Indian J Dermatol Venereol Leprol. 2024;91(1):49-58.
Chaichan W, Ruengorn C, Thavorn K, et al. Comparative safety profiles of individual second-generation H1-antihistamines for the treatment of chronic urticaria: a systematic review and network meta-analysis. J Allergy Clin Immunol Pract. 2023;11(8):2365-2381
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
